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Abstract
Introduction: Natalizumab is a new treatment for relapsing-remitting multiple sclerosis. Because of
limited experience of this treatment, medical professionals must be alert to possible side effects.
Case presentation: We present a 34-year-old Caucasian woman with relapsing-remitting multiple
sclerosis. She developed bruises on her legs after the first and second administrations of the new
monoclonal antibody, natalizumab. Clinical and laboratory investigations revealed no hematological
abnormalities. At the time of writing, she has remained on natalizumab treatment without any further
side effects.
Conclusion: In our patient, bruises on the lower extremities may be a benign side effect of
natalizumab. This is the first documented incidence of this side effect, and the patient did not require
discontinuation of natalizumab treatment.
Introduction
Natalizumab has recently been approved as a therapy for
patients with relapsing-remitting multiple sclerosis (RRMS)
andwithinadequate responsetoothertherapies[1].Asnew
therapeutic agents have evolved in the treatment of RRMS,
new risks may unfold for the patients. Here we present a
female patient suffering from RRMS, who was treated with
natalizumab and who developed bruises in both lower
extremities following the first and second infusions of
natalizumab.
Case presentation
A 34-year-old female Caucasian patient was given natalizu-
mab(300mg)forRRMS(accordingtoMacDonald’scriteria)
by intravenous infusion every 4 weeks; her score on the
Expanding Disability Status Scale was 4.0 [2]. The patient
hadnoothermedicalproblems,withtheexceptionofamild
reactive depression.
ThefirstclinicalepisodeinApril2001,consistedoffatigue,
asthenia,afeelingofimbalance,anddifficulties infineand
smoothmotorcoordinationwiththelefthand.Adiagnosis
of multiple sclerosis was made, based on clinical and
laboratory findings. The first relapse was in November
2001, at which point azathioprine was administered. She
developed a rash as a result of an allergic skin reaction to
azathioprine.In2002,shehadthreerelapsesandinterferon
beta was administered. Because of successive relapses, she
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mitoxantrone during the next 3 years. No remarkable
disease modification was achieved. She had three to four
relapses each year. During 2006, the patient had difficulty
waking up in the morning but she refused to receive
medical treatment because she wanted to get pregnant.
She had two relapses during the second half of 2006.
During the summer of 2007, following a new severe
relapse, she developed major difficulty in waking; this
precipitated her decision to undertake a natalizumab
treatment regimen. Since February 2007, she has been
treated with escitalopram (10 mg daily) for depression.
Thepatientunderwent thefirst infusionofnatalizumabon
4 September 2007. After a few hours, she presented with
twosmallbruisesonthefrontofherrightthigh.Thebruises
disappearedafter3to4days.However,duringthe11thday,
she developed bruises on the external side of her left calf
(Figure 1). A detailed history of the last 10 days revealed no
trauma or other mechanical reason for the bruising.
A clinical evaluation did not reveal any differences
compared with the pre-infusion situation. Laboratory
investigations, including blood and biochemical testing
of platelet activation, liver enzymes, and thyroid
hormones, as well as tests for collagen diseases and
coagulation, were all normal.
There are a few reported cases that have indicated an
unknown etiology of acquired FVIII inhibition, occurring in
patientswithMS[3].However,inourpatient,thelaboratory
test results for coagulation, including FVIII clotting activity,
were normal.
The bruising gradually disappeared during the next
2 weeks. As a result, a detailed report was submitted to
the National Medicine Organization according to Greek
legislation regarding medical treatment.
One month later, she underwent the second infusion
ofnatalizumabundercloseclinicalandlaboratorymonitor-
ing.Betweenthe10thand11thday,shepresentedagainwith
two small bruises on her left calf, which faded gradually
and disappeared over the next 2 weeks. No other changes
were noted in her clinical condition.
The third, fourth, and fifth natalizumab infusions (in
November,December,andJanuary,respectively)produced
no other side effects, and no further bruising occurred.
Discussion
According to the criteria of Karsh and Lasagna regarding
cause and effect relationships in reporting adverse drug
reactions, bruising on the legs in our patient could be
characterized as a conditional side effect following the first
and second natalizumab infusions [4]. No other clinical or
laboratory findings were noteworthy.
Conclusion
Although no clinical conclusions can be drawn from
a single case, natalizumab infusion is a new treatment, and
so we must pay close attention to newly occurring side
effects and clinical phenomena that correlate with
natalizumab administration, because their importance is
still unknown.
Abbreviation
RRMS, relapsing-remitting multiple sclerosis.
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